Changes in Cerebral Function in Treatment Naive HIV-1 Infected Subjects Commencing Either Boosted Atazanavir With Truvada or Boosted Darunavir With Maraviroc and Kivexa

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-01-31

Study Completion Date

2015-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to compare two different combination anti-HIV therapies over 48 weeks and to assess if differences in improvement in the function of the brain are observed over this period.

The study will compare anti-HIV therapy combinations which are currently in use.

The patients will not have had any previous treatment for their HIV infection.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

MARCH Central Nervous System Substudy

NCT01637233

HIV-1 Infection

COMPLETED

Clinical Trial of Brain-Penetrating HIV Drugs to Prevent Cognitive Impairment in China

NCT01340950

HIV Infections Central Nervous System Diseases Dementia

COMPLETED PHASE4

The CogNaive Study: Assessing Changes in Neurocognitive Function in Treatment Naïve HIV-1 Positive Subjects

NCT00540137

HIV Infections

COMPLETED PHASE4

HIV-1 Infected Adult Subjects With HIV-associated Neurocognitive Disorders Despite Effective Antiretroviral Therapy

NCT04266002

HIV-1-infection HIV Associated Neurocognitive Disorder

COMPLETED NA

The Maraviroc Central Nervous System (CNS) Study

NCT00982878

HIV Infections

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Impairment in neurocognitive(NC) function in HIV-infected subjects in the current anti-retroviraltreatment (cART) era has been associated with poor compliance with cART, reduced quality-of-life and increased mortality. Reported factors associated with the development of NC function impairment in HIV disease and risks associated with progression of such impairment include degree of immune suppression related to HIV infection, other chronic viral infections (such as chronic hepatitis C co-infection), age and central nervous system (CNS) antiretroviral drug exposure.

One modifiable factor which may be associated with the evolution of NC function impairment is the direct effect of cART on the central-nervous-system (CNS). Certain antiretroviral drugs such as zidovudine, lamivudine, abacavir, nevirapine, efavirenz and indinavir are known to achieve optimal exposure in the cerebro-spinal-fluid (CSF) whereas other drugs, such as the majority of the HIV-1 protease inhibitors penetrate less effectively. Studies to date suggest different cART regimens may have differing effects on NC performance. In the EuroSIDA study, the use of nucleoside-reverse-transcriptase inhibitors was found to specifically protect against the development of HIV related brain disease. More recently, in a small prospective study, ALTAIR, different effect on cerebral function was reported in subjects randomised to commence three different cART regimens.

The investigators propose, in a prospective, randomised study to assess the effects of two different antiretroviral regimens on NC function in HIV infected subjects commencing antiretroviral therapy for the first time.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV Impaired Cognition

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

standard care

treatment with:

* atazanavir 300 mg daily
* ritonavir 100 mg daily
* tenofovir 245 mg daily\*
* emtricitabine 200 mg daily\* \* as the fixed dose combination Truvada™

Group Type ACTIVE_COMPARATOR

standard care

Intervention Type DRUG

* atazanavir 300 mg daily
* ritonavir 100 mg daily
* tenofovir 245 mg daily\*
* emtricitabine 200 mg daily\*

Novel therapeutic approach

* darunavir 800 mg daily
* ritonavir 100 mg daily
* lamivudine 300 mg daily\*\*
* abacavir 600 mg daily\*\*
* maraviroc 150 mg once daily \*\* as the fixed dose combination Kivexa ™

Group Type ACTIVE_COMPARATOR

novel treatment

Intervention Type DRUG

* darunavir 800 mg daily
* ritonavir 100 mg daily
* lamivudine 300 mg daily\*\* and abacavir 600mgs daily\*\*
* maraviroc 150 mg once daily

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

standard care

* atazanavir 300 mg daily
* ritonavir 100 mg daily
* tenofovir 245 mg daily\*
* emtricitabine 200 mg daily\*

Intervention Type DRUG

novel treatment

* darunavir 800 mg daily
* ritonavir 100 mg daily
* lamivudine 300 mg daily\*\* and abacavir 600mgs daily\*\*
* maraviroc 150 mg once daily

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* HIV-1 infected males or females
* signed informed consent
* no previous antiretroviral treatment since HIV diagnosis
* screening CD4+ lymphocyte count \<= 350 cells/ųL
* susceptible to all currently licensed (Nucleoside Reverse Transcriptase Inhibitors) NRTIs, (Non-Nucleoside Reverse Transcriptase Inhibitors) NNRTIs and PIs based on HIV-1 genotypic resistance report
* CCR5-tropic HIV based on genotypic resistance testing\*

Exclusion Criteria

* • existing neurological disease

* hepatitis B or hepatitis C co-infection
* age under 18 years
* screening laboratory parameters \> grade 2 (with the exception of cholesterol and triglycerides)
* current history of major depression or psychosis
* recent head injury (past three months)
* current alcohol abuse or drug dependence
* active opportunistic infection or significant co-morbidities
* patients who are receiving other concomitant medication which are not permitted, as listed in appendix 2
* female patients of child-bearing potential who:

* have a positive serum pregnancy test at screening or during the study
* are breast feeding
* are planning to become pregnant
* all participants unwilling to use a barrier method of contraception
* patients who in the opinion of the investigator are not candidates for inclusion in the study

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No